SymBio™ Stent laden with a dual combination of pimecrolimus and paclitaxel, produced by Conor Medsystems, Inc., a Menlo Park, Calif.-based company, has been implanted into its first patient, company says. The SymBio stent’s dual drug capability is based on a proprietary reservoir-based technology described below:
Conor’s stent design incorporates hundreds of small holes, each acting as a reservoir into which drug-polymer compositions can be loaded. Through this proprietary design, Conor believes that it can greatly enhance control of the rate and direction of drug delivery, enable a wider range of drug therapies, and potentially increase the range of clinical applications of drug eluting stents…
Conor’s stent design permits controlled delivery of a single drug as well as having the capacity by design to delivery multiple drugs from a single stent. Two drugs can be deposited into the same reservoir or different reservoirs, and the drugs can be released independently of each other’s rate of release. This design element also enables delivery of multiple drugs in orthogonal directions.
Conor believes that its kinetic control, or control over the rate of drug release over time, and drug formulation capabilities offer the potential to make Conor a technology leader in the development of next generation stents. The company intends to penetrate this evolving market by developing additional products for the treatment of restenosis, including products with drugs other than paclitaxel, or products that deliver a combination of drugs. In addition, the company is investigating the potential applicability of it’s stent technology for the treatment of acute myocardial infarction, vulnerable plaque, reperfusion injury, and diabetic and metabolic syndrome restenosis.